Loading clinical trials...

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection

NCT04522830•Beech Tree Labs, Inc.

View on ClinicalTrials.gov

Summary

Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•40 years of age or older
•Provide written informed consent
•Have a SARS-COV-19 diagnostic test with positive results

Exclusion Criteria

•Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
•Subjects currently hospitalized
•Subjects who have received a COVID vaccination
•Subjects with a diagnosis of immunodeficiency

Locations (1)

Intermountain Clinical Reserach

Draper, Utah, United States

Key Dates

Start Date

July 30, 2020

Primary Completion Date

February 28, 2021

Completion Date

February 28, 2021

Last Updated

April 13, 2021

Enrollment

ACTUAL participants

Conditions

SARS-CoV-2 Infection

Interventions

BTL-TML-COVID

DRUG

Placebo

DRUG

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

RECRUITINGPHASE1

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058

SARS-CoV-2 Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Inclusion Criteria

Exclusion Criteria

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity